Isosorbide dinitrate and Halcion drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Isosorbide dinitrate (isosorbide dinitrate) and Halcion (triazolam). Common drug interactions include fall among females and loss of consciousness among males.

The phase IV clinical study analyzes what interactions people have when they take Isosorbide dinitrate and Halcion. It is created by eHealthMe based on reports of 43 people who take the same drugs from the FDA, and is updated regularly.

What is Isosorbide dinitrate?

Isosorbide dinitrate has active ingredients of isosorbide dinitrate. It is often used in angina. eHealthMe is studying from 13,180 Isosorbide dinitrate users. Check the latest studies of Isosorbide dinitrate.

What is Halcion?

Halcion has active ingredients of triazolam. It is often used in insomnia. eHealthMe is studying from 8,268 Halcion users. Check the latest studies of Halcion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 25, 2026

43 people who take Isosorbide dinitrate and Halcion together, and have interactions are studied.

Isosorbide dinitrate and Halcion drug interactions.

What are the common drug interactions of Isosorbide Dinitrate and Halcion, by gender? *:

female:

  1. Fall
  2. Fatigue (feeling of tiredness)
  3. Hip fracture
  4. Hypoxia (low oxygen in tissues)
  5. Interstitial pneumonia (lung disease characterized by progressive scarring of both lungs)
  6. Intervertebral disc protrusion (spinal disc protrusion)
  7. Left ventricular hypertrophy (the thickening of the myocardium (muscle) of the left ventricle of the heart)
  8. Leukopenia (less number of white blood cells in blood)
  9. Miosis (constriction of the pupil of the eye, resulting from a normal response to an increase in light)
  10. Mitral valve incompetence (inefficient heart valve)

male:

  1. Loss of consciousness
  2. Depressed level of consciousness
  3. Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)
  4. Acute circulatory failure (shock)
  5. Apnoea (suspension of external breathing)
  6. Arthralgia (joint pain)
  7. Asphyxia (a condition in which there is an extreme decrease in the concentration of oxygen in the body)
  8. Biliary tract disorder
  9. Blood creatine phosphokinase increased
  10. Cardiac failure

What are the common drug interactions of Isosorbide Dinitrate and Halcion, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Acute circulatory failure (shock)
  2. Apnoea (suspension of external breathing)
  3. Coma (state of unconsciousness lasting more than six hours)
  4. Convulsions (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled of muscles contract and relax rapidly and repeatedly)
  5. Cyanosis (lack of oxygen in body leads to blue appearance of skin ,mucous membrane nails)
  6. Dyspnoea (difficult or laboured respiration)
  7. Pallor

60+:

  1. Depressed level of consciousness
  2. Loss of consciousness
  3. Hepatitis c antibody positive
  4. Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
  5. Protein total decreased
  6. Proteinuria (presence of protein in the urine)
  7. Red blood cell count decreased
  8. Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)
  9. Alanine aminotransferase increased
  10. Anxiety

What are the existing conditions these people have? *

  1. Osteoporosis (bones weak and more likely to break): 5 people, 11.63%
  2. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 9.30%
  3. Volume Blood Increased: 3 people, 6.98%
  4. Hyperlipidaemia (presence of excess lipids in the blood): 3 people, 6.98%
  5. High Blood Cholesterol: 3 people, 6.98%
  6. Constipation: 3 people, 6.98%
  7. Cerebral Infarction (less blood supply to brain resulting tissue damage): 3 people, 6.98%
  8. Cardiac Failure Congestive: 3 people, 6.98%

* Approximation only. Some reports may have incomplete information.

Do you take Isosorbide dinitrate and Halcion?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Isosorbide dinitrate and Halcion:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Isosorbide dinitrate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Halcion:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Isosorbide dinitrate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Halcion and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on isosorbide dinitrate and triazolam (the active ingredients of Isosorbide dinitrate and Halcion, respectively), and Isosorbide dinitrate and Halcion (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: